High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases

被引:95
作者
Zackrisson, A. L. [1 ]
Lindblom, B. [1 ]
Ahlner, J. [1 ]
机构
[1] Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, Linkoping, Sweden
基金
瑞典研究理事会;
关键词
DEBRISOQUINE HYDROXYLATION CAPACITY; CYTOCHROME-P450; 2D6; SWEDISH POPULATION; S-MEPHENYTOIN; HUMAN BRAIN; POLYMORPHISM; PERSONALITY; PHENOTYPE; DRUG; GENOTYPE;
D O I
10.1038/clpt.2009.216
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In Sweden, about 550 individuals die every year of drug intoxication. Many of these drugs are metabolized by CYP enzymes such as CYP2D6 and CYP2C19. A lack of these enzymes, resulting in poor metabolism, can lead to adverse reactions and even to fatality. On the other hand, an ultrarapid metabolism can lead to insufficient drug plasma concentration, resulting in failure of treatment, or it can lead to high concentrations of active/toxic metabolites. The aim of this project was to study the genetic profile of individuals with regard to the presence of CYP2D6 and CYP2C19 genes, in cases of fatal intoxication (242), suicide (intoxications excluded) (262), and natural death (212). PCR, followed by pyrosequencing, was used for all the analyses. We found that, among those who died of suicide (suicide cases), there was a higher number carrying more than two active CYP2D6 genes (corresponding to the phenotype of ultrarapid metabolizer) as compared with those who died of natural causes (natural-death cases) (P = 0.007).
引用
收藏
页码:354 / 359
页数:6
相关论文
共 35 条
[1]  
Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441
[2]   HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].
ALVAN, G ;
BECHTEL, P ;
ISELIUS, L ;
GUNDERTREMY, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537
[3]   MOLECULAR-BASIS FOR RATIONAL MEGAPRESCRIBING IN ULTRARAPID HYDROXYLATORS OF DEBRISOQUINE [J].
BERTILSSON, L ;
DAHL, ML ;
SJOQVIST, F ;
ABERGWISTEDT, A ;
HUMBLE, M ;
JOHANSSON, I ;
LUNDQVIST, E ;
INGELMANSUNDBERG, M .
LANCET, 1993, 341 (8836) :63-63
[4]   PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN [J].
BERTILSSON, L ;
LOU, YQ ;
DU, YL ;
LIU, Y ;
KUANG, TY ;
LIAO, XM ;
WANG, KY ;
REVIRIEGO, J ;
ISELIUS, L ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :388-397
[5]  
BERTILSSON L, 1989, LANCET, V1, P555
[6]   Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry [J].
Brosen, K .
THERAPEUTIC DRUG MONITORING, 1996, 18 (04) :393-396
[7]   Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype [J].
Chang, M ;
Dahl, ML ;
Tybring, G ;
Gotharson, E ;
Bertilsson, L .
PHARMACOGENETICS, 1995, 5 (06) :358-363
[8]   Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain [J].
Chinta, SJ ;
Pai, HV ;
Upadhya, SC ;
Boyd, MR ;
Ravindranath, V .
MOLECULAR BRAIN RESEARCH, 2002, 103 (1-2) :49-61
[9]   ANALYSIS OF THE CYP2D6 GENE IN RELATION TO DEBRISOQUIN AND DESIPRAMINE HYDROXYLATION IN A SWEDISH POPULATION [J].
DAHL, ML ;
JOHANSSON, I ;
PALMERTZ, MP ;
INGELMANSUNDBERG, M ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (01) :12-17
[10]  
DAHL ML, 1995, J PHARMACOL EXP THER, V274, P516